1 |
Childs KS, Goodbourn S. Identification of novel co-repressor molecules for interferon regulatory factor-2[J]. Nucleic Acids Res, 2003, 31(12): 3016-3026.
|
2 |
Yeung KT, Das S, Zhang J, et al. A novel transcription complex that selectively modulates apoptosis of breast cancer cells through regulation of FASTKD2[J]. Mol Cell Biol, 2011, 31(11): 2287-2298.
|
3 |
Sécca C, Faget DV, Hanschke SC, et al. IRF2BP2 transcriptional repressor restrains naive CD4 T cell activation and clonal expansion induced by TCR triggering[J]. J Leukoc Biol, 2016, 100(5): 1081-1091.
|
4 |
Bruno A, Boisselier B, Labreche K, et al. Mutational analysis of primary central nervous system lymphoma[J]. Oncotarget, 2014, 5(13): 5065-5075.
|
5 |
Yin CC, Jain N, Mehrotra M, et al. Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia[J]. J Natl Compr Canc Netw, 2015, 13(1): 19-22.
|
6 |
Shimomura Y, Mitsui H, Yamashita Y, et al. New variant of acute promyelocytic leukemia with IRF2BP2-RARA fusion[J]. Cancer Sci, 2016, 107(8): 1165-1168.
|
7 |
Jovanovic JV, Chillón MC, Vincent-Fabert C, et al. The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia[J]. Leukemia, 2017, 31(3): 747-751.
|
8 |
Mazharuddin S, Chattopadhyay A, Levy MY, et al. IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid[J]. Leuk Lymphoma, 2018, 59(9): 2246-2249.
|
9 |
Stadhouders R, Cico A, Stephen T, et al. Control of developmentally primed erythroid genes by combinatorial co-repressor actions[J]. Nat Commun, 2015, 6: 8893.
|
10 |
Teng AC, Kuraitis D, Deeke SA, et al. IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression[J]. FASEB J, 2010, 24(12): 4825-4834.
|
11 |
Fang J, Li T, Zhu X, et al. Control of pathological cardiac hypertrophy by transcriptional corepressor IRF2BP2 (interferon regulatory factor-2 binding protein 2) [J]. Hypertension, 2017, 70(3): 515-523.
|
12 |
Chen HH, Keyhanian K, Zhou X, et al. IRF2BP2 reduces macrophage inflammation and susceptibility to atherosclerosis[J]. Circ Res, 2015, 117(8): 671-683.
|
13 |
Berron-Ruiz L. Immunological alterations in common variable immunodeficiency[J]. Rev Alerg Mex, 2017, 64(1): 87-108.
|
14 |
Keller MD, Pandey R, Li D, et al. Mutation in IRF2BP2 is responsible for a familial form of common variable immunodeficiency disorder[J]. J Allergy Clin Immunol, 2016, 138(2): 544-550. e4.
|
15 |
Hari A, Cruz SA, Qin Z, et al. IRF2BP2-deficient microglia block the anxiolytic effect of enhanced postnatal care[J]. Sci Rep, 2017, 7(1): 9836.
|
16 |
Cruz SA, Hari A, Qin Z, et al. Loss of IRF2BP2 in microglia increases inflammation and functional deficits after focal ischemic brain injury[J]. Front Cell Neurosci, 2017, 11: 201.
|
17 |
Ma YL, Xia JL, Gao X. Suppressing Irf2bp2 expressions accelerates metabolic syndrome-associated brain injury and hepatic dyslipidemia[J]. Biochem Biophys Res Commun, 2018, 503(3): 1651-1658.
|